Publish time: 2024-01-29 00:00:00
11A-1120608
US provisional application
Genetic modification of human primary natural killer (NK) cells has been a major challenge in PNK research and application. BaEV pseudotype lentiviral vector can efficiently transduce primary NK cells, and thus has shown great promise to overcome this challenge. However, the yield of BaEV lentivirus is typically low due to the syncytia effect of HEK293T during viral production. Here, we use CRISPR-Cas9 to generate a knockout HEK293T which can efficiently package high titer of BaEV lentiviral vector without syncytia. Also, this HEK293T knockout cell line has no aberrant defect in proliferation or metabolism. We further demonstrated that this packaging platform can accommodate different sizes of genetic cargo (e.g., CAR, dCas9) efficiently.
- This modified HEK293T cell line is able to improve the viral titer of BaEV lentivirus 5-10 fold.
- Easy to handle viral purification.
- Produce high titer lentiviral vector for chimeric antigen receptor expressing natural killer cells.
- Human natural killer cell, B cell, hematopoietic stem cell basic research and their related application
Steven Lin
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Efficient packaging of BaEV-Rless pseudotype lentivirus using a modified HEK293T cell line